Pfizer (PFE) Net Income towards Common Stockholders (2009 - 2026)

Pfizer (PFE) has 18 years of Net Income towards Common Stockholders data on file, last reported at -$13.0 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$13.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $12.0 million (up 33.33% YoY), and the FY2025 annual result was $25.0 million, up 127.27% from the prior year.
• Net Income towards Common Stockholders retreated to -$13.0 million in Q1 2026 per PFE's latest filing, from $25.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $34.0 million in Q3 2022 and troughed at -$26.0 million in Q4 2023.
• A 5-year average of $416666.7 and a median of -$3.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders slumped 1000.0% in 2022, then soared 950.0% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$21.0 million in 2022, then slipped by 23.81% to -$26.0 million in 2023, then soared by 69.23% to -$8.0 million in 2024, then jumped by 412.5% to $25.0 million in 2025, then sank by 152.0% to -$13.0 million in 2026.
• Business Quant data shows PFE's Net Income towards Common Stockholders at -$13.0 million in Q1 2026, $25.0 million in Q2 2025, and -$8.0 million in Q3 2024.